Breaking News

Moderna, Lonza Enter COVID-19 Vaccine Mfg. Pact

Aims to enable manufacturing of up to 1 billion doses per year with first batches of mRNA-1273 expected to be manufactured at Lonza U.S. in July 2020

By: Contract Pharma

Contract Pharma Staff

Moderna, Inc., a clinical stage biotechnology company developing messenger RNA (mRNA) therapeutics and vaccines, and Lonza Ltd. have entered a 10-year strategic collaboration for large scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against coronavirus (SARS-CoV-2) and additional Moderna products in the future.   The companies plan to establish manufacturing suites at Lonza’s facilities in the U.S. and Switzerland for the manufacture of mRNA-1273 at both sites. Technology transfer is e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters